

**WEST****End of Result Set**

Generate Collection

Print

1026  
ref

L41: Entry 2 of 2

File: USPT

May 19, 1998

DOCUMENT-IDENTIFIER: US 5753230 A

**\*\* See image for Certificate of Correction \*\***

TITLE: Methods and compositions useful for inhibition of angiogenesis

Detailed Description Text (88):

The phrase "monoclonal antibody" in its various grammatical forms refers to a population of antibody molecules that contain only one species of antibody combining site capable of immunoreacting with a particular epitope. A monoclonal antibody thus typically displays a single binding affinity for any epitope with which it immunoreacts. A monoclonal antibody may therefore contain an antibody molecule having a plurality of antibody combining sites, each immunospecific for a different epitope, e.g., a bispecific monoclonal antibody.

## CLAIMS:

1. A method for inhibiting angiogenesis in a solid tumor in a patient wherein cells of the tumor do not express levels of integrin .alpha..sub.v .beta..sub.3 detectable by immunohistochemistry comprising administering to said patient a composition comprising an angiogenesis-inhibiting amount of an anti-.alpha..sub.v .beta..sub.3 monoclonal antibody, whereby integrin .alpha..sub.v .beta..sub.3 expressed on the surface of vascular endothelial cells involved in said angiogenesis is contacted by said antibody resulting in inhibition in the blood supply to the tissue of said solid tumor.

16. A method for inhibiting angiogenesis in a solid tumor in a patient wherein cells of the tumor do not express levels of integrin .alpha..sub.v .beta..sub.3 detectable by immunohistochemistry with monoclonal antibody LM609 having ATCC accession number HB9537, comprising administering to said patient a composition comprising an angiogenesis-inhibiting amount of anti-.alpha..sub.v .beta..sub.3 monoclonal antibody, whereby integrin .alpha..sub.v .beta..sub.3 expressed on the surface of vascular endothelial cells involved in said angiogenesis is contacted by said antibody resulting in inhibition in the blood supply to the tissue of said solid tumor.

27. A method for inhibiting angiogenesis in an inflamed, angiogenic tissue of a patient, comprising administering to said patient a composition comprising an angiogenesis-inhibiting amount of an anti-.alpha..sub.v .beta..sub.3 monoclonal antibody, whereby integrin .alpha..sub.v .beta..sub.3 expressed on the surface of vascular endothelial cells involved in said angiogenesis in said angiogenic tissue is contacted by said antibody resulting in inhibition in the blood supply to said angiogenic tissue.